The new Butter Buds Non-Dairy 32X ingredient uses sunflower oil and other natural flavors to mimic the characteristics found in dairy fat in order to create medium-strong salted butter middle notes and buttery and savory base notes for maximum flavor impact, the firm says.
Butter Buds Inc. (Racine, WI), a supplier of dairy and non-dairy concentrates, launched a new non-dairy ingredient that it says offers the same taste and texture as dairy butter. The new Butter Buds Non-Dairy 32X ingredient uses sunflower oil and other natural flavors to mimic the characteristics found in dairy fat in order to create medium-strong salted butter middle notes and buttery and savory base notes for maximum flavor impact, the firm says.
Butter Buds Non-Dairy can be used in a wide range of foods. “Having Butter Buds’ hardworking ingredient solution in the matrix can often help formulators lower usage rates of other more costly ingredients to help control costs,” the firm’s press release adds. “Butter Buds Non-Dairy 32X is also shelf stable to minimize food storage refrigeration concerns and logistics costs, and is easy to use in manufacturing for a wide range of applications.”
Michael Ivey, the company’s national sales director, added, “This is an exciting flavor sensation that makes it possible for manufacturers to create satisfying and craveable non-dairy foods, without the risk of exposure to dairy allergens. It is also water soluble, so it’s very easy to integrate into existing formulations.”
HHS announces restructuring plans to consolidate divisions and downsize workforce
Published: March 27th 2025 | Updated: March 27th 2025According to the announcement, the restructuring will save taxpayers $1.8 billion per year by reducing the workforce by 10,000 full-time employees and consolidating the department’s 28 divisions into 15 new divisions.
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.